中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
NASH
Cancer (Lipid Metabolism and Oral Checkpoint Inhibitors)
Viral Diseases
Other Disease Areas
Products&Pipeline
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
2021
2020
2019
2018
2017
2016
2015
2014
Ascletis Joins Sagimet’s US$80 Million in Crossover Financing with Premium Investors
2021-02-11
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41
2021-01-12
«
1
2
3
